/* Pinterest verifcation tag */

Latest News

Multiple Sclerosis Online Course – New Dates for 2023

June 29, 2023 | Education, Life with MS, Study, Training

Due to popular demand, new course dates have been added for 2023. The next commencement date is 24th July 2023. If you have diagnosed MS and seek evidence-based information about MS & lifestyle, join this free & flexible 6-week online […]


MS in the News: Funded treatment for primary progressive multiple sclerosis

June 26, 2023 | Media, Progressive

Te Pātaka Whaioranga – Pharmac has started a consultation today for widening access for two treatments; ocrelizumab (branded as Ocrevus) as the first funded treatment for primary progressive multiple sclerosis, and emicizumab (branded as Hemlibra) for the treatment of all […]


‘Exhaustion and dread’ : Desperate carer calls for change

June 26, 2023 | Advocacy, Carer, Carers, Life with MS, Media, Petition, Progressive, Uncategorised

Speaking in support of the Carers Alliance petition, Maxine Hall, a carer for her husband with Multiple Sclerosis, speaks of her struggles and hopes that this campaign will at least raise awareness. View original article on Otago Daily Times: https://www.odt.co.nz/news/dunedin/exhaustion-and-dread-desperate-carer-calls-change […]


Media Release: Nationwide petition launched to fight “shocking” lack of fair support for carers

June 23, 2023 | Advocacy, Carer, Carers, Media, Petition

Media Release: Friday 5th June 2023 A powerful Alliance representing 56 national not-for-profits is demanding the Government stop “dragging its feet” to provide long overdue recognition and basic rights for the estimated one million largely unpaid New Zealanders struggling to […]


Major announcement: Pharmac Initiates Consultation to fund Ocrelizumab for Primary Progressive MS.

June 22, 2023 | Advocacy, Funding, Media, Progressive

Multiple Sclerosis New Zealand (MSNZ) is delighted to share that Pharmac have commenced consultation to fund Ocrelizumab for Primary Progressive MS. Currently, those with PPMS have no access to any disease modifying therapies. Ocrelizumab has been proven in trials to […]